Details for New Drug Application (NDA): 012928
✉ Email this page to a colleague
The generic ingredient in NOVRAD is levopropoxyphene napsylate anhydrous. Additional details are available on the levopropoxyphene napsylate anhydrous profile page.
Summary for 012928
Tradename: | NOVRAD |
Applicant: | Lilly |
Ingredient: | levopropoxyphene napsylate anhydrous |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 012928
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | EQ 50MG BASE/5ML | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No |
Profile for product number 004
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 100MG BASE | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No |
Profile for product number 006
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 50MG BASE | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No |
Complete Access Available with Subscription